Loading...
XNAS
QNTM
Market cap390mUSD
Dec 04, Last price  
10.00USD
1D
0.10%
1Q
-28.85%
IPO
134.19%
Name

FSD Pharma Inc

Chart & Performance

D1W1MN
XNAS:QNTM chart
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
-30.59%
Rev. gr., 5y
69.97%
Revenues
0k
0020,63065,169196,81900000
Net income
-14m
L-23.50%
00000-32,719,229-35,405,917-23,322,074-18,564,915-14,202,724
CFO
-7m
L-37.63%
00000-19,130,473-20,746,223-28,333,273-11,025,823-6,876,479

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

FSD Pharma Inc., a biotechnology company, operates in the pharmaceutical research and development business. Its lead candidate is FSD201, a palmitoylethanolamide for the treatment of inflammatory diseases. The company is also involved in the research and development of Lucid-Psych, a molecular compound identified for the treatment of mental health disorders; and Lucid-MS, a molecular compound identified for the treatment of neurodegenerative disorders. FSD Pharma Inc. is headquartered in Toronto, Canada.
IPO date
May 29, 2018
Employees
17
Domiciled in
CA
Incorporated in
CA

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑08
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT